Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The N-methyl D-aspartate receptor subtype 2B (NR2B or GluN2B) is a protein subunit that forms part of the NMDA receptor complex, a type of ionotropic glutamate receptor. NMDA receptors are heterotetrameric complexes typically composed of two obligatory NR1 (GluN1) subunits and two regulatory NR2 subunits (NR2A, NR2B, NR2C, or NR2D). The GluN2B/NR2B subunit contributes to the agonist binding site for glutamate and modulates channel properties. It plays a role in synaptic plasticity, learning, memory formation, central sensitization in chronic pain, and modulation of feeding behaviors. Mutations or dysregulation in GRIN2B have been implicated in various neurological disorders including intellectual disability, epilepsy syndromes, neurodevelopmental disorders such as autism spectrum disorder (ASD), schizophrenia risk modulation, chronic pain syndromes due to central sensitization mechanisms mediated by increased activity/expression at synapses involved in pain processing circuits.
Selective inhibition of GluN2B-containing NMDA receptor assemblies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on N-methyl D-aspartate Receptor Subtype 2B (NR2B).